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Abstract
West Nile virus (WNV) is a neurotropic, single-stranded RNA (ssRNA) flavivirus that can cause 
encephalitis, meningitis, and death in humans and mice. Human Toll-like receptor (TLR) 7, 8, and 
mouse TLR7 recognize viral ssRNA motifs and induce antiviral immunity. However, the role of 
mouse TLR8 in antiviral immunity is poorly understood. Here, we report that TLR8 deficient 
(Tlr8−/−) mice were resistant to WNV infection compared to wild-type (WT) controls. Efficient 
WNV clearance and moderate susceptibility to WNV-mediated neuronal death in Tlr8−/− mice was 
attributed to overexpression of Tlr7 and an interferon-stimulated gene Isg-56 expression, while 
reduced expression of the pro-apoptotic gene coding Bcl2-associated X protein (Bax) was 
observed. Interestingly, suppressor of cytokine signaling -1 (SOCS-1) directly associated with 
TLR8, but not with TLR7, indicating a novel role for TLR8 regulation of SOCS-1 function, while 
selective siRNA knockdown of Socs-1 resulted in induced Isg-56 and Tlr7 expression following 
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WNV infection. Collectively, we report that TLR8 coupling with SOCS-1 inhibits TLR7-mediated 
antiviral immunity during WNV infection in mice.
Introduction
West Nile virus (WNV) is a mosquito-borne, single-stranded (ss) RNA flavivirus that has 
caused significant morbidity and mortality in North America (1). In humans, WNV can 
cause a wide range of debilitating illnesses, from febrile-like illness to viral encephalitis, 
paralysis, and even death (2). However, the pathogenesis of WNV is still not clearly defined, 
and there is no approved WNV vaccine or specific antiviral therapeutic available for human 
use.
After mosquito inoculation, WNV initially infects skin Langerhans cells and macrophages, 
and then further replicates in draining lymph nodes, spleen, and other peripheral organs 
generating transient viremia. Prior to the development of specific humoral or T cell-
mediated immune responses, WNV may enter into the spinal cord and brain, leading to 
symptomatic neuronal dysfunction. Therefore, early control of WNV infection of neurons 
heavily relies on innate immunity. Toll-like receptors (TLRs) are a family of innate pattern 
recognition receptors (PRRs) that are located on either plasma-, or within endosomal-
membranes of host cells. WNV has been reported to be recognized by TLR3 (3) and TLR7 
(4), which play important roles during antiviral immunity by initiating a variety of cellular 
signal transduction cascades, including the Myd88 dependent and independent cascades to 
control infection (3-8), and initiates the expression of interferon stimulated genes (Isg), 
which can inhibit viral replication and transcription/translation of viral proteins through 
various antiviral mechanisms (9, 10). On the other hand, TLR signaling can be compromised 
when single nucleotide polymorphisms (SNPs) are present in Tlr2, Tlr3, Tlr4, Tlr7, Tlr8, 
and Tlr9 genes that have been associated with defective antiviral immunity in human 
immunodeficiency virus (11, 12), herpes simplex virus type 2 (13), and Rift Valley fever 
virus (14) infections.
Human TLR8 can recognize viral ssRNA, but mouse TLR8 has been described as non-
functional (15-17) and its natural ligand remains unknown. This may be due to a deletion of 
five amino acids in the leucine-rich repeat ectodomain of TLR8 in mice, which is a region 
critical for recognition of viral ssRNA (18, 19). Although somewhat controversial (20), one 
study has suggested that mouse TLR8 could recognize specific DNA motifs in vaccinia virus 
(21), while another report has suggested that TLR8 recognizes a combination of 
imidazoquinoline and poly-T oligodeoxynucleotides (22), however the natural ligand of 
mTLR8 still remains elusive. Interestingly, overexpression of murine TLR8 neither activates 
interferon regulatory factor 3 (IRF-3) nor interferon-α in HEK293T cells, suggesting TLR8 
may inhibit the type I interferon pathway (23). In addition, TLR8 knockout (Tlr8−/−) mice 
develop lupus-like autoimmunity due to increased TLR7 function (24-26). Therefore, the 
function of TLR8 in mice is complicated and its role during antiviral immunity needs to be 
further investigated.
Signal transduction pathways that are triggered following cytokine and PRR engagement 
must be tightly regulated to prevent aberrant immune responses. Regulation is maintained 
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through protein tyrosine phosphatases, protein inhibitors of activated STATs (PIAS), and 
suppressors of cytokine signaling (SOCS) proteins (27, 28). Socs genes are expressed at a 
relatively low levels in an inactivated state, but are rapidly transcribed following TLR or 
cytokine engagement (28). For instance, Socs-1 and Socs-3 are induced following WNV 
infection, possibly acting as neuroprotective responses within the brain to regulate aberrant 
inflammation (29). SOCS-1 has been shown to inhibit STAT-1 signaling of IFNα (30), 
suggesting SOCS-1 regulates type I IFNs. Antiviral immunity involves the secretion of type 
I IFNs, such as IFNα and IFNβ, from viral-infected cells and act through a paracrine or 
autocrine mechanism, which engages the JAK/STAT signal transduction pathway to induces 
a multitude of antiviral molecules that directly or indirectly inhibit viral infection (31). 
Interferon stimulated gene-56 (Isg-56, ISG-56/IFIT-1) has been shown to be induced by 
active STAT-1/2 and IRF-3/5/7/9 molecules following type I IFN signaling transduction (32) 
and protects neurons from WNV infection (33, 34).
Herein, we report that TLR8 partners with SOCS-1 to control TLR7-mediated antiviral 
immunity in the central nervous system (CNS) of mice during WNV infection.
Materials and Methods
Ethics statement and biosafety
All animal experimental procedures were reviewed and approved by the Institutional Animal 
Care and Use Committees at The University of Southern Mississippi (USM) and Yale 
University. All the in vitro experiments and animal studies involving live WNV were 
performed by certified personnel in biosafety level 3 (BSL3) laboratories following standard 
biosafety protocols approved by USM and Yale University Institutional Biosafety 
Committees.
Viruses, animals, cells, and chemicals
WNV isolate (CT2741) was kindly provided by Dr. John F. Anderson at the Connecticut 
Agricultural Experiment Station. To prepare virus stocks, WNV was propagated and titered 
in Vero cells (ATCC CCL-81) by a plaque assay, as previously described (35). Tlr8−/− mouse 
breeding pairs were provided by Dr. Richard A. Flavell and wild-type (WT, C57BL/6J) 
control mice were purchased from the Jackson Laboratories (Bar Harbor, ME). Seven week-
old WT and Tlr8−/− mice were inoculated intraperitonealy with 2000 plaque forming units 
(PFUs) of WNV in 1% gelatin for survival analysis and tissue collection, according to 
previous publications (36-38).
BMDCs were isolated from WT or Tlr8−/− mice (3 to 6 month old) and cultured as 
previously described (39). Briefly, mouse bone marrow cells were collected from femurs and 
grown in DMEM supplemented with 10% FBS, 2% plasmacytoma cell medium containing 
GM-CSF (J588L), 1% Pen/Strep, 1% L-glu and 50 μM of β-mercaptoethanol until 
maturation (11 days). Mature BMDCs were either infected with WNV or stimulated with the 
TLR7 ligands CL264 (Invitrogen) or Loxoribine (Invitrogen).
Murine primary mixed neuronal cultures were isolated from WT and Tlr8−/− mice (6 to 12 
month old), as previously described with some modifications (40). Briefly, whole brains 
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were isolated in ice-cold HEPES-buffered saline (HBS), minced and triturated in Papain (2 
mg/ml) in HBS and incubated for 15 minutes at 37°C. Following incubation, cells were 
plated on poly-ornithine pre-treated plates for 20 minutes at 37°C, followed by a gentle wash 
with HBS to remove cellular debris. Cells were cultured in DMEM:F12 (1:1) medium 
(Thermo Scientific) supplemented with 1% Pen/Strep, 10% FBS, 1% L-glu, and glucose 
(4.5g/l). On day 11, supernatant was removed and replaced with Neurobasal®-A media (Life 
Technologies) supplemented with 2% B-27 (Life Technologies), 10% FBS, 1% L-glu and 
1% Pen/Strep. The mature neurons were infected with WNV (MOI = 1) for 24 or 48 hr.
Murine Neuro-2a cell line (CCL-131) and the murine macrophage cell line, RAW 264.7 
cells (TIB-71) were purchased from ATCC and were maintained in DMEM containing 10% 
FBS and 1% Pen/Strep at 37°C with 5% CO2.
TLR7 and TLR8 ligands CL264, CL075, loxibrine and PolydT were all purchased from 
Invivogen and used at indicated concentrations and time points.
Interferon bioassay
Bioactive type I IFN in culture supernatant was analyzed by a previously described method 
(41) that measured IFN pre-treated protection against encephalomyocarditis virus (EMCV) 
in a susceptible cell line (L929, ATCC). Briefly, culture supernatant collected from WT and 
Tlr8−/− mice BMDCs that were infected in vitro with WNV for 24 hr (MOI = 5) were UV-
inactivated (10 minutes at 120 mJ/s). The crude, UV inactivated supernatant was added to 
monolayers of L929 cells (cultured in DMEM supplemented with 10% FBS and 1% Pen/
Strep) in 96-well flat bottom plates. Following incubation for 14 h at 37°C, medium was 
removed and cells were infected with EMCV (MOI = 10) for 7 hr. ECMV-mediated cell 
death was measured using a CellTiter 96 aqueous cell proliferation assay kit (Promega) and 
an ELx808 ultra microplate reader (BIO-TEK Instruments, Inc.). The percentage (%) of 
protected cells was calculated as described (41), according to the following formula: (optical 
density at 492 nm [OD492] of supernatant-treated EMCV-infected cells / OD492 of non-
EMCV-infected cells × OD492 of EMCV-infected cells) / (OD492 of non-EMCV-infected 
cells) × 100%).
Quantitative PCR (qPCR)
Mouse tissues, blood, or cultured cells were collected for total RNA extraction with 
TRIreagent (Molecular Research Center, Inc.) and converted into first strand cDNA using 
the iSCRIPT™ cDNA synthesis kit (Bio-Rad). qPCR assays were performed using iTAQ™ 
polymerase supermix for probe-based assays (Bio-Rad) or iQ™ SYBR® Green Supermix 
polymerase (Bio-Rad). WNV-envelope (WNV-E) gene and mouse gene primers and probes 
sequences were adapted according to previous publications: WNV-E (4), β-Actin (42), Tlr7 
(24), Irf-7 (43), Ifn-α (43), Isg-56 (43), Isg-54 (44), Isg-49 (44), Ifn-β (43), and Socs-1 (45). 
Primers were designed for murine Bax, forward 5’-TGCTAGCAAACTGGTGCTCA-3’ and 
reverse 5’-TAGGAGAGGAGGCCTTCCCAG-3’. Data were presented either as relative fold 
change (RFC) by the 2−ΔΔCT method, using β-actin as a housekeeping gene, or was 
expressed as a ratio of target gene to β-actin copy numbers. All the primers and probes were 
synthesized either by Integrated DNA Technologies or Applied Biosystems.
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siRNAs were designed using the Thermo Scientific siRNA designing tool (siDESIGN 
Center) targeting murine Isg-56 (10nM, 5’-
GUAAGUAGCCAGAGGAAGGUGAUGCUU-3’) or a scrambled sequence (5’-
ACUACUUCAGGUGUGAGCUAAUAUACC-3’) and were transfected with RNAiMAX 
Lipofectamine reagent (Life Technologies) into Neuro-2a cells in OPTI-MEM medium (Life 
Technologies) for 20 minutes. DMEM containing 2% FBS was then added and cell were 
cultured for 24 hr. Following incubation, media was removed and cells were infected with 
WNV (MOI = 5) for 48 hr. Cells were then collected for qPCR and flow cytometric 
analyses.
Murine siRNAs targeting murine Socs-1 (Santa Cruz Biotechnologies) were transfected into 
RAW 264.7 cells (6 × 105 cells/ml) following manufactures recommendation, with some 
minor changes. Briefly, lipoplexes were prepared in OPTI-MEM media (Life Technologies) 
by mixing siRNA (25 nM) and transfection reagent (Santa Cruz Biotechnology) for 30 
minutes. Cells and lipoplexes were mixed in 12-well plates and incubated in OPTI-MEM for 
24 hr. DMEM containing 2% FBS was added to the cells followed by infection with WNV 
(MOI = 0.1) and cells were cultured for and additional 24 hr. Following infection, cells were 
collected and prepared for qPCR analysis.
Immunocytochemistry and immunofluorescence assays
Murine BMDCs were isolated, and plated at 3 × 105 cells / well and infected with WNV at 
day 11. Infected cells were then fixed with 4% paraformaldehyde (PFA) in PBS for 15 
minutes at room temperature (RT). The cells were washed with PBS, blocked with 2% 
normal goat serum (Life Technologies) containing 0.4% Triton-X for 1 hr at room 
temperature (RT), and probed with monoclonal mouse-anti-flavivirus glycoprotein E IgG 
antibody (4G2, ATCC D1-4G2-4-15 HB-112) overnight at 4°C. The cells were then washed 
with PBS and probed with goat polyclonal anti-mouse-HRP IgG (KPL) for 2 hr at RT. 
Immuno-positive cells were developed with TrueBlue peroxidase substrate (KPL). Images 
were taken using an Axiostar Plus light microscope (Zeiss) and mean pixel intensity was 
quantified using ImageJ (version 1.48), as previously described (46).
Similarly, primary neurons were isolated from mice, infected with WNV, and fixed as 
described above. After a 1 hr blocking step at RT with 2% normal goat serum containing 
0.4% Triton-X, neurons were probed with mouse monoclonal-anti-WNV-E (1:50, Abcam) 
and rabbit polyclonal anti-ISG-56 antibodies (1:100) overnight at 4°C. The cells were then 
washed with PBS and probed with polyclonal goat-anti-mouse-FITC IgG (eBioscience) and 
polyclonal goat-anti-rabbit-DyLight594 IgG (Thermo Scientific) for 2 hr at RT. The cells 
were then washed with PBS, mounted using Vectashield® mounting medium containing 
DAPI, and imaged as above.
For brain immunohistochemistry, WNV infected WT and Tlr8−/− mice were euthanized (day 
6 p.i) and perfused with ice-cold PBS. Half brain was fixed overnight in 4% PFA, followed 
by frozen tissue cyroprotection with daily changes in 10%, 20%, and 30% sucrose in PBS. 
Brain tissues were frozen in Tissue-Plus™ O.C.T. buffer (Fisher Healthcare) and midsagittal 
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sections (10 μm) were cut using a Tissue-Tek®Cryo3® microtome/cryostat (Sakura) and 
mounted on pre-cleaned Superfrost® Plus microscope slides (Fisher Scientific). Apoptotic 
measurement of brain tissue was detected by TACS® 2 TdT-Fluor in situ apoptosis detection 
kit (Trevigen) following manufacturer’s recommendations and images were acquired using a 
confocal LSM 510 microscope (Zeiss).
Immunoblotting and immuoprecipitation
Mouse whole brains were prepared with lysis buffer containing 50 mM Tris-HCl, 150 mM 
NaCl, and 0.25% sodium dodecyl sulfate (SDS), 0.25% Sodium Deoxycholate, 1 mM EDTA 
and 1% Proteinase inhibitor cocktail (Sigma P8340). Protein concentration in lysates was 
quantified by a Bradford Assay (Bio-Rad) and cell lysates were mixed with 2× Laemmli 
buffer (Bio-Rad) containing 0.1% β-mercaptoethanol (Sigma), boiled at 95°C for 5 minutes, 
and rapidly spun down. Whole-cell protein lysates (5-10 μg/well) were separated by 
polyacrylamide gel electrophoresis and were transferred to a nitrocellulose membrane (Bio-
Rad). The membrane was blocked with 5% bovine serum albumin (BSA) for 1 hr and 
probed with rabbit polyclonal anti-TLR7 (Cell Signaling Technology), rabbit polyclonal 
anti-ISG-56 (Pierce Antibodies), rabbit monoclonal anti-STAT-1 (Cell Signaling 
Technology), rabbit monoclonal anti-IRF-7 (Abcam) antibodies in 5% BSA overnight at 
4°C. The immunolabeled membrane was then probed with secondary HRP-conjugated goat 
anti-rabbit IgG (Jackson ImmunoResearch Laboratories, Inc.) for 2 hr. β-Tubulin-HRP (Cell 
Signaling Technology) was used as a loading control. Membranes were developed with 
SuperSignal West Pico Chemiluminescence Substrate (Thermo Scientific) and images were 
acquired using a ChemiDoc™ XRS+ System (Bio-Rad).
For immunoprecipitation, Neuro-2a cell lysates were prepared as mentioned above, and were 
mixed with rabbit polyclonal anti-TLR7 (1:50, Cell Signaling Technology) or rabbit 
polyclonal anti-TLR8 (1:50, Sigma) antibodies for 2 hr at RT, washed in 1× TBS containing 
0.05% Tween 20, and 0.5 M NaCl, and were mixed with Dynabeads Protein G (Life 
Technologies) for an additional 1 hr. Samples were then washed and resuspended in 2× 
Laemmli buffer containing 0.1% β-mercaptoethanol, boiled at 95°C for 5 minutes, and 
rapidly spun down. Proteins from whole-cell lysates were separated by polyacrylamide gel 
electrophoresis and transferred to a nitrocellulose membrane. Membranes were then probed 
with a rabbit polyclonal anti-SOCS-1 antibody (1:1000, Sigma) in 5% BSA overnight at 
4°C, followed by probing with a secondary peroxidase-conjugated goat anti-rabbit IgG 
(Jackson ImmunoResearch Laboratories, Inc.) for 2 hr, and developed as above. Loading 
control input bands were detected following back incubation with the rabbit polyclonal anti-
TLR8 antibody (Sigma).
Flow cytometry
TLR7 expression in blood cells—Blood samples were collected in EDTA-coated tubes 
from WNV infected WT and Tlr8−/− mice by retro-orbital bleeding and red blood cells 
(RBC) were lysed by adding RBC lysis buffer (Sigma). Blood cells were washed two times 
to remove lysed RBCs and resuspended in flow cytometry buffer (PBS +2% FBS) at 5 × 105 
cells/ ml. Cells were probed overnight at 4°C with rabbit polyclonal anti-TLR7 antibody 
(Cell Signaling Technology), washed two times with flow buffer, and probed with secondary 
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goat-anti-rabbit-DyLight594 IgG (Thermo Scientific) for 2 hr at RT. Cells were then washed 
two times and analyzed in a BD LSRFortessa flow cytometer (BD Biosciences) and data 
were acquired using BD FACSDIVA™ version 7.0 (BD Biosciences). Cells probed only with 
secondary antibody were used as controls for fluorescence gating.
TLR7, WNV antigen and IFNα in BMDCs—WT and Tlr8−/− BMDCs were infected 
with WNV (MOI = 5) for 24 hr, as described above. The cells were fixed with 2% PFA and 
permeabilized with PBS +0.05% Tween-20 (permeabilization buffer). The cells were 
incubated overnight with mouse monoclonal anti-WNV-Envelope IgG2b (1:100, Abcam) 
antibody, rat monoclonal anti-IFNα IgG1 (1:100, Abcam), or rabbit polyclonal anti-TLR7 
(1:100, Cell Signaling Technology) followed by two washes with permeabilization buffer, 
and probed with a secondary goat-anti-mouse-IgG antibody conjugated to FITC (Santa Cruz 
Biotechnology), goat-anti-rat-IgG antibody conjugated to Alexa Fluor® 555 (Molecular 
Probes), or goat-anti-rabbit-IgG antibody conjugated to DyLight594 (Thermo Scientific), 
respectively, for 2 hr at RT in dark. For WNV antigen detection, cells were washed two 
times with permeabilization buffer, and resuspended in DAPI (100 μM) for 10 minutes, then 
analyzed FITC mean fluorescent expression (MFI) with a flow cytometer (BD 
LSRFortessa). DAPI expression was analyzed with a microplate reader (BioTek® 
SynergyHI) using Gen5 (version 2.07) software to determine the ratio of FITC+ MFI 
normalized to DAPI+ cells.
Secreted IFNα in cell medium—UV inactivated supernatant collected from WT and 
Tlr8−/− BMDCs were incubated with rat monoclonal anti-IFNα antibody (1:50) over night at 
4°C, on a rocker to create immune complex formation. In a separate tube, Dynabeads 
Protein G (Life Technologies) were washed in buffer (TBS + 0.05% Tween-20, 0.5M NaCl) 
and added to the supernatant containing IFNα antibodies for 1 hr at RT. The beads were then 
magnetically separated from the remaining supernatant, washed, and secondary anti-rat-
antibody conjugated to AlexaFluor® 555 (1:1000) was added. After incubation for 2 hr at 
RT, the beads were detached from the immune complexes with an elution buffer (0.1M 
glycine, pH 2.0) and neutralized in Tris-HCL (pH 9.0) buffer. The MFI of the beads was 
analyzed by flow cytometry, as above.
Apoptosis Assay—Apoptosis was measured using a modified annexin V and propidium 
iodide (PI) apoptosis assay (47). Briefly, Neuro-2a cells were collected and resuspended in 
annexin V binding buffer followed by staining with annexin V conjugated to Alexa Fluor® 
488 (Molecular Probes) and PI (Sigma). Cells were then washed with annexin V binding 
buffer and fixed in a 1% PFA for 10 minutes on ice and then were incubated in RNase A (50 
μg/ml, Sigma) for 15 minutes at 37°C, washed twice in PBS, and analyzed by flow 
cytometry.
Statistical analyses
Data were compared with either a Student’s t-test or two-way analysis of variance with 
Bonferroni post-hoc analysis. Survival curves were analyzed using a Kaplan-Meier analysis. 
All statistical analyses were performed by using GraphPad Prism software (version 6.0).
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TLR8 signaling in mice facilitates WNV infection
Our previous report demonstrated that TLR7 signaling protects mice from lethal WNV 
infection (4) and Tlr7 expression is up-regulated in TLR8 deficient (Tlr8−/−) mice (24). To 
investigate the potential role of TLR8 during WNV infection in mice, we challenged Tlr8−/− 
and WT mice intraperitoneally (i.p.) with 2000 plaque forming units (PFU) of WNV and 
monitored mice twice daily for morbidity and mortality for up to 21 days. The Kaplan-Meier 
survival analysis shows that 52% of Tlr8−/− and 26% of WT mice survived of lethal WNV 
infection (Fig. 1A), indicating that TLR8 signaling facilities WNV infection in mice. To 
further confirm this observation, we measured viral burden in the blood and brains of WNV-
infected mice by quantitative polymerase chain reaction (qPCR). Consistent with the 
survival data, the qPCR results show the lower expression of WNV-E transcripts in blood of 
Tlr8−/− mice compared to WT controls at day 4 and the brain at days 4 and 6 post-infection 
(p.i.) (Fig. 1B-D). These results indicate that TLR8 signaling in mice plays a negative role in 
WNV immunity by facilitating WNV replication. Type I interferons (IFN) play essential 
roles in viral clearance and control of WNV burden in mice (48, 49). Therefore we assessed 
the expression of type I IFNs in blood samples collected from WNV-infected Tlr8−/− and 
WT mice at day 1 to day 4 p.i. by qPCR. The results showed that Tlr8−/− mice have 
increased expression of Ifn-α at days 1 to 4, and Ifn-β at days 1 and 2, compared to WT 
controls following WNV infection (Fig. 1E and F). In addition, IFN regulatory factor-7 
(Irf-7) and IFN stimulated gene-56 (Isg-56) measured in blood of WNV-infected Tlr8−/− 
mice showed an increasing trend in gene expression (Fig. 1G and H). In summary, these 
results indicate that TLR8 facilitates WNV infection in mice possibly due to the down-
regulation of type I IFN-dependent antiviral response.
TLR8 in mice negatively regulate TLR7-mediated WNV immunity
Since naïve Tlr8−/− mice express higher levels of Tlr7 (24), we measured the expression of 
TLR7 in blood leukocytes collected from WNV-infected WT and Tlr8−/− mice by flow 
cytometry at day 1 post-WNV infection. The results indicate an increased expression of 
TLR7 in leukocytes of WNV-infected Tlr8−/− mice compared to WT controls (Fig. 2A). To 
further investigate the potential role of TLR8 in regulating the expression of Tlr7 during 
WNV infection, we infected bone marrow derived dendritic cells (BMDCs) from Tlr8−/− and 
WT mice with WNV (multiplicity of infection, MOI = 5) in vitro and measured the 
expression of Tlr7 by qPCR. In line with the in vivo results, the qPCR results showed a 
higher basal expression level of Tlr7 in BMDCs from Tlr8−/− mice compared to WT 
controls, which was further amplified following WNV infection, indicating overexpressed 
Tlr7 in the absence of TLR8 (Fig. 2B). Consistent with this, we also confirmed TLR7 
expression on BMDCs from Tlr8−/− mice was further increased following WNV infection at 
the protein level by flow cytometry (supplemental (s)Fig. 1A). To assess the antiviral 
function of Tlr7 overexpression, we stimulated BMDCs from Tlr8−/− and WT mice with the 
TLR7-specific ligand CL264 (5 μg/ml) and measured the expression of type I IFN by qPCR. 
We found higher levels of Ifn-α (Fig. 2C) and Ifn-β (sFig. 1B) expression in BMDCs 
generated from Tlr8−/− mice compared to WT controls at multiple time points, suggesting 
that overexpression of TLR7 in Tlr8−/− mice may induce stronger antiviral immunity. To 
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confirm this, we infected BMDCs from Tlr8−/− and WT mice with WNV (MOI = 5) or an 
alphavirus, chikungunya virus (CHIKV, MOI = 5), and assessed the transcript levels of Ifn-α 
and Ifn-β at 24 hr post-infection (p.i.) by qPCR. The results show higher expression of Ifn-α 
(Fig. 2D) and Ifn-β (sFig. 1C) in BMDCs generated from Tlr8−/− mice than WT controls in 
response to both type of infections, WNV or CHIKV, suggesting a response not only specific 
to WNV. In addition, intracellular and secreted IFN-α was also shown to be increased in 
Tlr8−/− BMDCs as compared to WT controls following WNV infection in a flow cytomertic 
assay (Fig. 2E and F). Moreover, we measured gene expression of signaling proteins 
involved in the type I IFN response, and found that WNV infection significantly induced the 
expression of both Irf-7 and Isg-56 in Tlr8−/− BMDCs compared to WT controls at 24 hr p.i. 
with WNV (Fig. 2G and 2H). To further confirm higher expression of type I IFN in the 
absence of TLR8, we measured bioactive type I IFN in cell culture supernatant of WNV-
infected Tlr8−/− and WT BMDCs, as previously described (41). The IFN bioassay further 
confirmed that BMDCs generated from Tlr8−/− mice produced more IFN than those from 
WT controls during WNV infection (Fig. 2I). Since BMDCs generated from Tlr8−/− mice 
have increased antiviral immunity, we expected these cells to be more efficient in controlling 
WNV infection. Indeed, we found that BMDCs from Tlr8−/− mice are more resistant to 
WNV infection in vitro compared to those from WT mice, as measured by reduced WNV 
antigen expression (Fig. 2 J and K, and sFig. 1D and E). In summary, these results show that 
TLR8 signaling in mice down-regulates the expression of Tlr7, which results in reduced 
antiviral immune response against WNV infection.
TLR8 negatively regulates antiviral immunity within the murine central nervous system 
(CNS)
WNV can cause severe CNS infection and can lead to injury and death of neurons in both 
mice and humans. Since we observed reduced viral burden in the brains of WNV-infected 
Tlr8−/− mice and increased expression of Tlr7 and other antiviral genes in Tlr8−/− BMDCs 
infected in vitro with WNV, we asked whether TLR8 also regulates antiviral immunity in the 
brains of WNV-infected mice. On day 4 post-WNV infection (2000 PFU/mouse, i.p.), 
Tlr8−/− and WT mice were euthanized, perfused with ice-cold PBS, and whole brains were 
collected for qPCR and western blotting analyses of TLR7 and other antiviral molecules. 
Consistent with the results from BMDC, uninfected Tlr8−/− mice exhibited increased basal 
expression of Tlr7 in brains compared to WT controls, which was further increased 
following WNV infection (Fig. 3A). These results suggest that increased Tlr7 expression in 
brains of Tlr8−/− mice may result in better capability to recognize and respond to 
neuroinvasive WNV. To further test this, we measured the expression of Irf-7, Ifn-α and Ifn-
β in brain tissues collected from WNV-infected Tlr8−/− and WT mice by qPCR, and the 
results indicated slightly higher expression of Irf-7 (Fig. 3B) and a trend for increased 
expression of Ifn-α (Fig. 3C), while the expression of Ifn-β remained unaltered (data not 
shown). Since type I IFNs were not robustly increased in the brains of Tlr8−/− mice, but viral 
burden was significantly reduced (Fig. 1C and D), we sought to examine if Tlr8−/− mice 
overexpress other antiviral genes. To test this, we examined the expression of Isg-56, Isg-54, 
and Isg-49. Interestingly, the expression of Isg-56 was increased (Fig. 3D) in Tlr8−/− mice 
brains following WNV infection was enhanced, while the expression of Isg-54 and Isg-49 
were not significantly altered (data not shown). In addition, we also confirmed higher 
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expression TLR7, ISG-56, IRF-7 and STAT-1 in brain lysates of WNV-infected Tlr8−/− mice 
at protein levels by an immunoblotting assay (Fig. 3E). Together, these results confirm that 
Tlr8−/− mice express higher level of TLR7 in brain tissue, which may lead to strong antiviral 
responses via increased expression of ISG-56, IRF-7 and STAT-1.
We next analyzed the expression of Tlr7 and antiviral genes in primary mixed neuronal 
cultures isolated from WNV infected (MOI = 1, 24 hr) WT and Tlr8−/− mice whole brain 
homogenates in vitro. The qPCR analysis indicate that Tlr7, Irf-7, and Ifn-α were all 
increased following WNV infection in Tlr8−/− neurons compared to WT controls (Fig. 3F-
H), suggesting that the TLR7-mediated IFN signaling pathway may increase neuronal 
resistance against WNV infection in Tlr8−/− mice. We further assessed if the expression of 
IFN-stimulated genes were also altered in WNV-infected Tlr8−/− neurons by qPCR. 
Consistent with in vivo brain tissue results (Fig. 3D), we found increased expression of 
Isg-56 (Fig. 3I), along with increased Isg-54 and Isg-49 in the Tlr8−/− neurons infected in 
vitro with WNV compared to WT controls (data not shown). In line with increased antiviral 
immunity, immunofluorescence microscopy show reduced WNV antigen and increased 
ISG-56 expression in WNV-infected Tlr8−/− neurons compared to WT controls (Fig. 3J and 
K). In summary, these results indicate that TLR8 inhibits antiviral immunity against WNV 
infection leading to enhance viral replication within the CNS.
TLR8 expression results in increased WNV-induced apoptosis that is CNS region-specific
One of the major cell death pathways that occur in WNV neuroinvasive disease is apoptosis, 
in particular via the induction of the apoptotic mediated gene, Bcl-2 associated X protein 
(Bax) (50, 51). To examine the degree of WNV-mediated cellular apoptosis in Tlr8−/− and 
WT brain tissue, whole brains were isolated at day 6 p.i. and were analyzed by a TUNEL 
assay. The TUNEL assay showed that Tlr8−/− mice had significantly reduced cell death of 
WNV-permissive Purkinje neurons of the cerebellum (52-57) compared to WT controls (Fig. 
4A), with no observable differences in any other regions of the brain. Interestingly, we found 
that the gene expression of Bax (Fig. 4B), along with antiviral genes Isg-56 and suppressor 
of cytokine signaling (Socs-1) were significantly altered only in the spinal cords and 
cerebellar regions of Tlr8−/− mice at day 4 p.i. (data not shown), suggesting that antiviral 
immunity confined viral-induced apoptosis within these regions of the brain. In line with 
this, previous reports have suggested that the expression (56) and neuroprotective role of 
ISG-56 does indeed localize to these specific region of CNS (34). WT and Tlr8−/− neurons 
infected with WNV (MOI = 1) for 24 hr in vitro were also analyzed for Bax expression by 
qPCR, indicating reduced neuronal Bax-dependent apoptosis occurs in Tlr8−/− mice 
following WNV infection (Fig. 4C). These results indicate that TLR8 signaling counteracts 
antiviral immunity, possibly by down-regulation of Isg-56 expression, favoring WNV-
induced neuronal death.
Since higher expression of ISG-56 in brains of Tlr8−/− mice following WNV infection is 
associated with the reduced Bax expression, we tested if the Bax-mediated apoptosis is 
dependent on Isg-56 expression. For this, we used siRNAs to knockdown Isg-56 in mouse 
Neuro-2a cells, and assessed Bax expression and apoptosis following WNV infection in 
vitro. Isg-56-specific siRNAs were transfected into Neuro-2a cells for 24 hr and the cells 
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were further infected with WNV (MOI = 5) for an additional 48 hr. The efficiency of 
siRNAs to knockdown Isg-56 expression was confirmed by qPCR in WNV-infected 
Neuro-2a cells (Fig. 4D). Interestingly, knockdown of Isg-56 leads to increased replication 
of WNV (Fig. 4E) and the expression of Bax (Fig. 4F), suggesting that WNV replication 
may be inhibited by ISG-56 expression. To test if apoptosis is the direct consequence of 
increased Bax expression in siRNA-Isg-56-transfected Neuro-2a cells, we stained WNV-
infected Neuro-2a cells with annexin-V and measured apoptosis by flow cytometry. The 
results confirmed that knocking down Isg-56 expression increased apoptosis of WNV-
infected Neuro-2a cells (Fig. 4G and H). Collectively, these data indicate that ISG-56 is an 
essential antiviral molecule that controls WNV-induced neuronal apoptosis.
TLR8 regulates SOCS-1 signaling, which controls Isg-56 and Tlr7 expression
Socs-1 has been shown to be induced by WNV (29) and its expression inhibits antiviral 
responses, such as type I IFNs (58). We found that the expression of Socs-1 was 
significantly reduced in brain tissue and neurons in Tlr8−/− mice following WNV infection 
(Fig. 5A and B), suggesting that TLR8 regulates Socs-1 expression during WNV infection. 
To test if TLR8 directly regulates SOCS-1 function, we performed an immunoprecipitation 
(IP) assay in Neuro-2a cells in the presence of various TLR7, and suspected mouse TLR8 
ligands (22). Interestingly, we found that SOCS-1 co-precipitates with TLR8, but not TLR7 
(Fig. 5C), even in the presence of TLR7 and TLR8 ligation. These results suggest that TLR8 
may directly control SOCS-1 function within neurons in mice. To test if Isg-56 is regulated 
by Socs-1, we transfected a mouse macrophage cell line (RAW 264.7) with siRNA targeting 
Socs-1 for 24 hr and infected these cells for an additional 24 hr with WNV (MOI = 0.1), 
followed by qPCR analysis. We found that Socs-1 was slightly reduced following siRNA 
transfection in WNV-infected mouse RAW 264.7 cells (Fig. 5D) that was coupled to 
increased Isg-56 (Fig. 5E) and Tlr7 (Fig. 5F) expression. These results indicate that SOCS-1 
signaling down-regulates Tlr7 and Isg-56 expression in mice. Since SOCS-1 associates with 
TLR8 directly (Fig. 5C) in mice, SOCS-1 may couple with TLR8 to inhibit the expression of 
Tlr7 and subsequently its downstream signaling molecules, such as Isg-56, facilitating WNV 
infection in mice (Fig. 6).
Discussion
Human and mouse Tlr7 and Tlr8 share a high degree of structural and phylogenetic 
similarity, and are located only 70 kb apart on the same X chromosome (17, 24). 
Functionally, both human and mouse TLR7, and human TLR8 recognize viral ssRNA 
motifs. However, mouse TLR8 does not recognize viral ssRNA, which led to the belief that 
TLR8 may be non-functional in mouse in terms of sensing viral ssRNAs (16). It has since 
been suggested that mouse TLR8 recognizes DNA motifs of vaccinia virus (21) which 
however, was contradicted by another report (20). It has also been suggested that mouse 
TLR8 can recognize a combination of imidazoquinoline and poly-T oligodeoxynucleotides 
(22), however the natural ligand for mTLR8 still remains unknown. Our research group and 
others have demonstrated that mice deficient in TLR8 (Tlr8−/−) overexpress Tlr7 and 
manifest systemic autoimmunity due to development of a subset of B cells that produce anti-
small nuclear ribonucleoproteins (snRNPs), anti-ribonucleoproteins (RNPs), and anti-DNA 
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antibodies (24-26, 59). On the other hand, transgenic mice that overexpress human TLR8 
result in down-regulated mouse Tlr7 expression (15). Based on these reports, it can be 
speculated that TLR8 in mice might have multiple functions to regulate immunity other than 
serving as a PRR. We previously reported that TLR7 plays an important role in the 
recognition and mitigation of WNV infection in mice (4). However, the role of mouse TLR8 
during WNV pathogenesis has not been previously studied.
Defective Tlr7 and type I Ifn genes are contributing factors to not only WNV susceptibility, 
but to enhanced WNV-induced disease (4, 60, 61). In the current report, we found that TLR8 
deficiency in mice induced a strong antiviral immune response, which facilitated efficient 
control of viral burden and increased survival of mice after lethal WNV challenge. In line 
with previous reports that showed TLR8 negatively regulated TLR7 expression in mouse 
dendritic cells (24, 25), Tlr8−/− mice had increased gene expression of Tlr7 in multiple 
tissues compared to WT controls, which was further amplified following WNV infection. 
While the mechanism by which increased Tlr7 expression in the absence of viral infection 
was not further explored in this study, it has been suggested that deficiency in TLR signaling 
could be compensated for by other PRRs (62). Due to their close loci proximity and 
redundancy in pattern recognition (17, 63), TLR7 signaling may over-compensate for a loss 
of TLR8, as the reciprocal has been identified in TLR7 deficiency (64). Yet, in the context of 
viral infection, it may be possible that TLR8 directly or indirectly represses Tlr7 
transcription in mice. Based on the evidence that TLR8 co-precipitates with SOCS-1, and 
knockdown of Socs-1 by siRNA leads to increased Tlr7 transcription in WNV-infected RAW 
264.7 cells, we may conclude that TLR8 couples to SOCS-1 to suppress the expression of 
Tlr7 and its downstream signaling during WNV infection in mice. However, we cannot 
exclude the possibility that expression of Tlr7 may be also indirectly enhanced by type I IFN 
responses induced by other PRRs, such as RIG-I and MDA5, in response to WNV infection 
(9). While we only measured inactive IRF-7 expression, active IRF-7-p has been described 
to act as a master transcription factor for IFNα (65, 66), which regulates the induction of 
Isg-56 and Tlr7 and thus, requires further study (67, 68). Furthermore, there was an overall 
increase in expression levels of TLR7, IRF-7, and ISG-56 in Tlr8−/− mice, in particular 
within primary neurons; therefore, involvement of multiple regulatory pathways may 
contribute to hyperactive antiviral immunity to control viral infection. In line with this, it has 
been described that functional polymorphisms in the human Tlr8 gene may predispose 
individuals to differential viral susceptibility (14, 69-72). For instance, TLR8C-A haplotypes 
are associated with dengue fever susceptibility, while TLR8G-G haplotypes are associated 
with dengue hemorrhagic fever susceptibility (71) and truncated Tlr8 protects against HIV, 
as rapid decay of Tlr8 mRNA results in induced TNF-α signaling (70). Therefore, TLR8 
may function to suppress antiviral immunity through negative regulation of TLR7 signaling.
ISG-56 (IFIT-1), along with other IFIT family members including ISG-54 (IFIT-2) and 
ISG-49 (IFIT-3) protect neurons from WNV infection (33, 34, 73). These molecules are 
enhanced by type I IFNs during viral infection (9, 56) and function by binding to the 5’-PPP 
end of viral RNA, mRNA, or to the translation initiation factor eIF-3, to inhibit the initiation 
of viral/host protein translation (33, 67, 74). WNV-infected Tlr8−/− mice expressed higher 
levels of type I IFNs and Isg-56 in various tissues compared to WT controls. Moreover, 
increased expression of Isg-54 (IFIT-2) and Isg-49 (IFIT-3) were also observed in WNV-
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infected Tlr8−/− mice neurons, suggesting a vast array of enhanced antiviral immunity. 
Consistent with the previous report that IFITs are vital antiviral proteins that work in concert 
to control viral infection within the CNS (75), we further verified the importance of Isg-56 
during WNV infection in Tlr8−/− mice by knocking down its expression, which resulted in 
an increased WNV-induced neuronal apoptosis mediated by Bax, highlighting an important 
role for ISG-56 during WNV-induced neuronal death.
Tissue and cellular tropism of WNV is regulated by antiviral gene localization (56, 76) and 
IFIT molecules play a crucial role in controlling viral spread within neurons (33). 
Additionally, the cerebellum and choroid plexus express Isg-56 following WNV infection 
(33), and IFNβ treatment induces a higher expression of Isg-56 in cerebellar cells (56). In 
line with this, we observed a significant increase of Isg-56 only within the spinal cord and 
cerebellar regions of Tlr8−/− mice brains, together with reduced morbidity, suggesting 
neuropathogenesis of WNV may be limited by antiviral control only within these regions of 
the CNS. Overexpression of Tlr7 in the CNS has been linked to the induction of IL-6 
dependent dendrite retraction (64) and leads to cell death by induction of a CNS-specific 
TIR adaptor protein called Sterile alpha and HEAT/Armadillo motif (SARM) (77). Yet in the 
presence of WNV infection, SARM is necessary to reduce WNV burden and prevent cell 
death, as Sarm−/− mice are susceptible to WNV infection (78). In addition, TLR7 agonists, 
imiquimod and ssRNA, have been described to induce neuronal cell death (79). However, 
there are no phenotypic or behavioral defects observed in naïve Tlr8−/− mice, and increased 
percent of survival and reduced TUNEL signals observed within Tlr8−/− mice brains 
following lethal WNV challenge, suggest that increased TLR7 does not cause any apparent 
neuronal damage in our experimental conditions. Furthermore, the expression of TLR7 
observed in the brains of Tlr8−/− mice is relatively mild, which suggests that only 
dramatically increased expression/signaling by TLR7 may lead to neuronal damage.
Suppressor of cytokine signaling (SOCS)-1, a negative regulator of IFN signaling, can be 
induced following viral challenge (29, 80-82). SOCS-1 suppresses a multitude of signaling 
molecules, such as the Mal adaptor protein in TLR4 signaling (83), IRAK-4 (84), TRAF6 
(85), type I IFNs (30, 58), JAKs (86) and transcriptional promoters including STAT-1 (58, 
87), IRF7 (88) and p53 (89). Importantly, Socs-1 knockdown in Japanese encephalitis virus 
(JEV)-infected macrophages resulted in reduced viral load and increased ISGs, suggesting 
that SOCS-1 may directly regulate expression of ISGs (90). Since Tlr8−/− mice had a 
hyperactive IFN response and reduced Socs-1, we hypothesized that TLR8 signaling may 
regulate Socs-1 expression. It has been reported that TLR7/8 signaling induces the 
expression of Socs-1 in HEK293 cells, yet these studies did not rule out if this signaling is 
dependent on TLR7 or TLR8 alone, or an effect of combined TLR7 and TLR8 ligation (91). 
In our report, we demonstrated that SOCS-1 partnered with TLR8, but not TLR7, suggesting 
SOCS-1 utilizes TLR8 as an adaptor molecule for its regulation. This interaction is possible 
as there are 13 phospho-tyrosine residues located on the cytoplasmic domain of TLR8, but 
not on TLR7 (92), which provides ample docking sites for the SH2 regions of SOCS-1 to 
bind to TLR8. SOCS proteins function to directly associate and inhibit adaptor proteins and 
their signaling pathways via protein degradation (83). However, we observed a stable 
interaction between TLR8 and SOCS-1 24 hr post stimulation in Neuro-2a cells, suggesting 
a non-canonical role for TLR8 SOCS-1 regulation that requires further investigation.
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In conclusion, TLR8 couples with SOCS-1 to exacerbate neuroinvasive WNV infection in 
mice, by negative regulation of TLR7-mediated antiviral immunity in mice. The 
identification of a novel role for SOCS-1 in TLR8-mediated immune regulation may have 
broad implications in understanding antiviral immunity in both mice and humans. Although 
human TLR8 regulation of TLR7 with SOCS-1 was not studied in this manuscript, the 
therapeutic potential of inhibiting the TLR8 pathway may provide an alternative antiviral 
strategy to combat WNV infection in humans, which requires further investigation.
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Figure 1. Tlr8−/− mice are resistant to lethal WNV infection
WT and Tlr8−/− mice were infected with 2000 PFU/mouse of WNV and monitored twice 
daily for mortality and morbidity for up to 21 days. (A) Survival analysis of WT and Tlr8−/− 
mice by Kaplan-Meier analysis. The ratio of WNV-envelope (E) to β-actin in blood (B) and 
brain samples at day 4 (C) and day 6 (D) p.i., collected from euthanized mice was 
determined by qPCR. The absolute gene copy ratio of Ifn-α (E), Ifn-β (F), Irf-7 (G) and 
Isg-56 (H) to β-actin were measured in blood samples by qPCR at indicated days p.i. (n = 
5-8 per group). The survival data were analyzed using a Kaplan-Meier log-rank test (* 
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denotes p < 0.05). Gene expression data were analyzed using a two-tailed, Student’s t-test (* 
denotes p < 0.05 ± 1 SEM). All reported experiments were performed twice.
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Figure 2. TLR8 signaling negatively regulates TLR7-mediated antiviral immunity
(A) Flow cytometric histograms and mean fluorescent intensity (MFI) analysis of TLR7 
expression in blood collected from WNV-infected WT (grey outline), Tlr8−/− (black outline), 
and secondary only IgG isotype control (grey filled) mice (n = 6-8 per group) at day 1 p.i.. 
QPCR analysis for gene expression of (B) Tlr7, (D) Ifn-α, (G) Irf-7, and (H) Isg-56 in WT 
and Tlr8−/− mice BMDCs infected in vitro with WNV or CHIKV (MOI = 5) for 24 hr. 
BMDCs from WT and Tlr8−/− mice were stimulated in vitro with the TLR7 ligand CL264 (5 
μg/ml) for indicated time points and gene expression of Ifn-α (C) was measured by qPCR. 
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Flow cytometic analysis of IFN-α expression in BMDCs infected with WNV (MOI = 5) for 
24 hr (E) and IFN-α production in the media (F) of WT and Tlr8−/− BMDCs infected with 
WNV (MOI = 5) for 24 hr. (I) IFN production in the culture media of WNV-infected WT 
and Tlr8−/− BMDCs were measured by an IFN-bioassay. (J) Immunocytochemistry images 
of BMDCs infected with WNV for 24 hr (400 × magnification, inset 900 × magnification). 
(K) Flow cytometric analysis of WNV-Envelope protein in BMDCs infected with WNV 
(MOI = 5) for 24hr. WT (grey outline), Tlr8−/− (black outline), and secondary only IgG2b 
isotype control (grey filled) mice. The gene expression profile of Figure 1B is represented as 
a mean unitless ratio of gene of interest to β-actin ± 1 SEM, while all remaining qPCR 
profiles were normalized to β-actin and were plotted as relative fold change (RFC). All 
qPCR assays were performed three times and were analyzed using a two-tailed, Student’s t-
test (* denotes p < 0.05 ± 1 SEM, n = 3 per group). The IFN-bioassay and the flow 
cytometric analysis in blood was performed once, and the flow cytometric analysis in 
BMDCs (n = 3 per group) was performed twice, and analyzed using a two-tailed, Student’s 
t-test (* denotes p < 0.05 ± 1 SEM).
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Figure 3. Tlr8−/− mice have increased antiviral immunity in CNS tissue
Gene expression analysis of Tlr7 (A), Irf-7 (B), Ifn-α (C), Isg-56 (D) to β-actin in whole 
brains from WNV-infected WT and Tlr8−/− mice at day 4 p.i. by qPCR (n = 6-8 per group). 
(E) Immunoblotting analysis of TLR7 (140 kDa), total STAT-1 (94/87 kDa) ISG-56 (56 
kDa), total IRF-7 (51 kDa), and β-Tubulin (55 kDa) from whole brain lysates of WNV-
infected WT and Tlr8−/− mice at day 4 p.i. (n = 6-8 per group). Primary mixed neuronal 
cultures isolated from WT and Tlr8−/− mice (6–12 month old, n = 3 per group) were cultured 
to maturity in vitro and infected with WNV (MOI = 1) for 24 hr. Gene expression of Tlr7 
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(F), Irf-7 (G), Ifn-α (H), Isg-56 (I), and WNV-E (J) to β-actin were measured by qPCR. (K) 
WNV-infected neurons probed with anti-WNV-E (green) or anti-ISG-56 (red) antibodies 
were imaged using a confocal LSR 510 microscope at 100 × magnification. All qPCR assays 
were analyzed by a two-tailed Student’s t-test (* denotes p < 0.05, and ns denotes non 
significant, ± 1 SEM). qPCR assays were performed three times and the immunoblotting 
assays were performed two times.
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Figure 4. Reduced apoptosis in WNV-infected Tlr8−/− mice is localized to CNS-specific regions
(A) WT and Tlr8−/− mice brains were isolated at day 6 p.i. and imaged to detect cellular 
apoptosis in midsagittal brain sections. TUNEL labeling (green, white arrow) and DAPI 
(blue, dashed white arrow) were merged indicating reduced TUNEL immunofluorescence 
was observed in Tlr8−/− Purkinjie neurons of the cerebellum compared to WT controls (n = 
4 per group). Gene expression profile of Bax (B) to β-actin in different brain regions: 
Cerebellum, Cortex (Ctx), Midbrain (Mid), Olfactory Bulb (OB), and spinal cords (SC) from 
WNV-infected WT and Tlr8−/− mice (n = 9-22 per group) at day 4 p.i. were analyzed by 
Paul et al. Page 26













qPCR. Primary mixed neuronal cultures isolated from WT and Tlr8−/− mice (6 to 12 month 
old, n = 3 per group) were cultured to maturity in vitro and infected with WNV (MOI = 1) 
for 24 hr. Gene expression of Bax (C) to β-actin was analyzed by qPCR. Gene expression of 
Isg-56 (D), WNV-E (E) and Bax (F) were measured by qPCR in Neuro-2a cells transfected 
with siRNA targeting Isg-56 (10 nM) for 24 hr, followed by infection with WNV (MOI = 5) 
for an additional 48 hr. (G and H) Neuro-2a cells were transfected with siRNA targeting 
Isg-56 or with a scrambled siRNA control and infected with WNV, as above. Cells were 
stained with annexin V and PI followed by flow cytometric analysis (n = 3 per group). Brain 
sections were imaged using a confocal LSR 510 microscope at 63 × magnification. All 
qPCR and flow cytometric analyses were performed three times and analyzed using a two-
tailed Student’s t-test (* denotes p < 0.05, ± 1 SEM).
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Figure 5. TLR8 signaling regulates Socs-1 expression
Gene expression of Socs-1 (A) to β-actin (n = 6-8 per group) was analyzed in whole brains 
from WNV-infected WT and Tlr8−/− mice at day 4 p.i. by qPCR. Primary mixed neuronal 
cultures isolated from WT and Tlr8−/− mice (6 – 12 month old, n = 3 per group) were 
cultured to maturity in vitro and infected with WNV (MOI = 1) for 24 hr and gene 
expression of Socs-1 (B) to β-actin was measured by qPCR. (C) Co-immunoprecipitation of 
TLR7 or TLR8 with SOCS-1 was performed in Neuro-2a cells stimulated with PolydT (10 
μM), CL075 (10 μM) or both agonists for 24 hr by using anti-TLR7 or anti-TLR8 antibodies 
coated magnetic beads and Western blot analysis of SOCS-1. RAW 264.7 cells were 
transfected with siRNA targeting Socs-1 followed by infection with WNV (MOI = 0.1) for 
24hr and gene expression analysis of Socs-1 (D), Isg-56 (E) and Tlr7 (F) to β-actin was 
measured by qPCR. All qPCR assays were performed two independent times and analyzed 
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using a two-tailed, Student’s t-test (* denotes p < 0.05, ± 1 SEM). Immunoprecipitation 
experiments were performed two times.
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Figure 6. TLR8 signaling regulates SOCS-1 expression, leading to increased inhibition of 
antiviral immunity following WNV infection
Representative image of wild-type and Tlr8−/− mice cells that are infected with WNV and 
the proposed mechanism of signaling. In wild-type cells infected with WNV, TLR8 
signaling results in increased SOCS-1, which negatively regulates antiviral immunity via 
direct STAT-1 inhibition (58) or possibly through ISG-56 inhibition, which results in 
increased viral load, triggering the p53-Bax-dependant apoptosis pathway (50, 51). 
Conversely, in TLR8 deficient cells (Tlr8−/−) SOCS-1 is not adequately induced, therefore 
antiviral immunity is minimally inhibited, resulting in increased Isg-56, Irf7, and Tlr7 
expression, which ultimately amplifies the TLR7 signaling pathway, while successfully 
controlling viral load and reducing virus-induced apoptosis. The non-canonical function of 
SOCS-1 directly binding to TLR8 and not TLR7, in both mock and TLR7 and TLR8 
stimulated cells, is yet to be further elucidated.
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